| Contributors |
|
xi | |
| Preface |
|
xv | |
| In Memoriam |
|
xvii | |
|
|
| In Memoriam |
|
xix | |
|
|
|
|
|
|
1 Basic Principles of Clinical Pharmacology Relevant to Cardiology |
|
|
3 | (14) |
|
|
|
2 The Placebo Effect in the Treatment of Cardiovascular Disease |
|
|
17 | (14) |
|
|
|
|
|
3 Importance of Medication Adherence in Cardiovascular Disease Treatment |
|
|
31 | (8) |
|
|
|
|
|
4 Health Economic Considerations in Cardiovascular Drug Utilization |
|
|
39 | (18) |
|
|
|
|
|
|
|
|
5 Alpha- and Beta-Adrenergic Blocking Drugs |
|
|
57 | (30) |
|
|
|
6 Central and Peripheral Sympatholytics |
|
|
87 | (6) |
|
|
|
|
|
7 Cholinergic and Anticholinergic Drugs |
|
|
93 | (6) |
|
|
|
|
|
8 Calcium Channel Blockers |
|
|
99 | (22) |
|
|
|
|
|
9 The Renin-Angiotensin Axis: Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers |
|
|
121 | (26) |
|
|
|
|
|
|
|
10 The Renin-Angiotensin Axis: Direct Renin Inhibition |
|
|
147 | (10) |
|
|
|
|
|
11 Diuretic Therapy in Cardiovascular Disease |
|
|
157 | (20) |
|
|
|
|
|
|
|
12 Magnesium, Potassium, and Calcium as Cardiovascular Disease Therapies |
|
|
177 | (12) |
|
|
|
|
|
|
|
189 | (16) |
|
|
|
|
|
|
|
14 The Organic Nitrates and Nitroprusside |
|
|
205 | (12) |
|
|
|
|
|
15 Ranolazine: A Piperazine Derivative |
|
|
217 | (6) |
|
|
|
|
|
|
|
16 Nonspecific Antihypertensive Vasodilators |
|
|
223 | (4) |
|
|
|
|
|
|
|
227 | (30) |
|
|
|
|
|
|
|
18 Antiplatelet and Other Antithrombotic Drugs |
|
|
257 | (48) |
|
|
|
|
|
|
|
|
|
305 | (18) |
|
|
|
|
|
|
|
323 | (54) |
|
|
|
|
|
21 New Aspects of Combination Therapy: Focus on Hypertension |
|
|
377 | (8) |
|
|
|
22 Pharmacotherapy for Smoking Cessation |
|
|
385 | (12) |
|
|
|
23 Pharmacotherapy of Obesity |
|
|
397 | (16) |
|
|
|
|
|
|
|
24 Heart Disease and Treatment of Diabetes Mellitus |
|
|
413 | (12) |
|
|
|
|
|
|
|
|
|
25 Prostacyclins, Endothelin Inhibitors, and Phosphodiesterase-5 Inhibitors in Pulmonary Hypertension |
|
|
425 | (14) |
|
|
|
|
|
26 Selective and Nonselective Dopamine-Receptor Agonists |
|
|
439 | (6) |
|
|
|
|
|
27 Natriuretic Peptides: Nesiritide |
|
|
445 | (6) |
|
|
|
|
|
28 Vasopressin and Vasopressin Receptor Antagonists |
|
|
451 | (10) |
|
|
|
|
|
|
|
|
|
|
|
461 | (12) |
|
|
|
|
|
|
|
|
30 Alternative and Complementary Medicine for Preventing and Treating Cardiovascular Disease |
|
|
473 | (20) |
|
|
|
31 Cardiovascular Drug-Drug Interactions |
|
|
493 | (26) |
|
|
|
|
|
|
|
32 Pediatric Cardiovascular Pharmacology |
|
|
519 | (28) |
|
|
|
|
|
|
|
33 Drug Therapy of Cerebrovascular Disease |
|
|
547 | (18) |
|
|
|
|
|
|
|
34 Drug Treatment of Peripheral Vascular Disorders |
|
|
565 | (28) |
|
|
|
|
|
35 Drug Treatment and Prevention of Infective Endocarditis and Rheumatic Fever |
|
|
593 | (16) |
|
|
|
|
|
36 Cytokines and Myocardial Regeneration: A Novel Therapeutic Option for Acute Myocardial Infarction |
|
|
609 | (10) |
|
|
|
|
|
|
|
37 Cardiovascular Drugs in Development |
|
|
619 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
1 Pharmacokinetic Properties of Approved Cardiovascular Drugs |
|
|
633 | (20) |
|
2 Therapeutic Use of Available Cardiovascular Drugs |
|
|
653 | (68) |
|
3 Guide to Cardiovascular Drug Use in Pregnancy and with Nursing |
|
|
721 | (8) |
|
4 Dosing Recommendations of Cardiovascular Drugs in Patients with Hepatic Disease and/or Congestive Heart Failure |
|
|
729 | (6) |
|
5 Dose Adjustment in Patients with Renal Insufficiency |
|
|
735 | (8) |
|
6 Selected Cardiovascular Medications and Gender Issues |
|
|
743 | (2) |
|
7 Pharmacokinetic Changes, Route of Elimination, and Dosage Adjustment of Selected Cardiovascular Drugs in the Elderly |
|
|
745 | (6) |
|
8 Selected Cardiovascular Medications and Ethnic Issues |
|
|
751 | (2) |
| Index |
|
753 | |
Biežāk uzdotie jautājumi par e-grāmatām